BD Gains From Solid Global Base, Headwinds AnticipatedYahoo Finance #Fiscal_2019February 12, 2019
While solid developments and a strong global foothold boost the stock, a few headwinds are anticipated in fiscal 2019.
In the past year, BD’s shares have rallied 15% against the industry’s decline of 0.4%.
Over the past 60 days, the Zacks Consensus Estimate for the company’s fiscal third-quarter earnings per share moved up 0.6% to $3.25.
Becton, Dickinson and Company Price and Consensus
Last month, BD announced the FDA approval of its second-generation BD Nano pen needle for more reliable subcutaneous injection depth.
Per management, overseas revenue growth was backed by strong performance by all three segments in the quarter.
Although pressure from raw materials partially eased in the fiscal first quarter, management expects a 2% headwind from it in fiscal 2019.
Notably, each of these stocks currently carries a Zacks Rank #2 (Buy).
Wright Medical’s long-term earnings growth rate is expected at 11%.
Zacks’ Top 10 Stocks for 2019